Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PHVS
PHARVARIS N.V.
NASDAQ
$35.25
▼ DOWN 1.15% (-0.41)

KEY STATISTICS

Market Cap$2.46 B
52w High$38.13
52w Low$20.65
Dividend Yield—
Frequency—
P/E-11.07
Volume483.51K
Shares Out.69.88M

COMPANY

LEADERSHIP

Berndt Axel Edvard Modig
CHIEF EXECUTIVE
Berndt Axel Edvard Modig

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 4, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
148

PRICE TARGET

Target High$74.00
Target Low$40.00
Target Median$52.00
Target Consensus$52.71

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

PRICE

$35.25 ▼ DOWN 1.15% (−$0.41)
$35.60$36.00$36.409:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM35.25

About Pharvaris N.V.

https://pharvaris.com ↗

Pharvaris N.V. is a clinical-stage biopharmaceutical company developing therapies for rare diseases like hereditary angioedema, with multiple Phase I and II treatments including PHA121, PHVS416, and PHVS719.

INDUSTRY

Biotechnology

A PRODUCT PHARVARIS N.V. IS KNOWN FOR

Deucrictibant
Deucrictibant

Deucrictibant is a late-stage oral drug candidate in Phase 3 trials for hereditary angioedema, targeting acute attacks and prevention by acting as a bradykinin B2 receptor antagonist.

COMPETITORS

COMPETITOR
BCRX COMPARE
IONS COMPARE
KA KALV COMPARE
PHAR COMPARE
TAK COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
55
LISTED HERE
14
RANKED BY POSITION SIZE
IBB
0.07% · 217.5K
XXSC.L
0.05% · 56.0K
MMS.PA
0.17% · 33.8K
UEFD.AS
0.14% · 29.9K
ONEQ
0.01% · 27.0K
GWX
0.09% · 24.1K
BBC
0.72% · 10.2K
VISM.AX
0.01% · 6.1K
IBBQ
0.16% · 4.5K
BIB
0.08% · 2.5K
FPXE
0.31% · 428
TNXT
0.05% · 280
TISC
0.01% · 240
GTPE
0.01% · 79

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.72%
HOLDERS
141
TOP 12 OF 141 · RANKED BY POSITION SIZE
General Atlantic, L.P.
8.0M sh · $200.38M
Fmr LLC
6.6M sh · $227.03M
Foresite Capital Management Iv, LLC
4.8M sh · $165.24M
Venbio Partners LLC
4.6M sh · $160.57M
Viking Global Investors LP
3.7M sh · $103.21M
Eqt Fund Management S.A R.L.
3.4M sh · $118.42M
Deerfield Management Company, L.P. (Series C)
3.4M sh · $116.74M
Bain Capital Life Sciences Investors, LLC
3.2M sh · $79.37M
Commodore Capital LP
2.4M sh · $60.34M
Wellington Management Group Llp
2.4M sh · $82.75M
Polar Capital Holdings Plc
2.3M sh · $80.45M
Paradigm Biocapital Advisors LP
1.8M sh · $45.8M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Modig Berndt
Sale · 2.3K shares
2026-08-14
★
OFFICER: PRESIDENT
Lu Peng
Sale · 117 shares
2026-08-12
★
OFFICER: PRESIDENT
Lu Peng
Sale · 109 shares
2026-08-11
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Modig Berndt
Sale · 2.3K shares
2026-07-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 3
BUY 2
MARKET OUTPERFORM 1
OVERWEIGHT 1
NEUTRAL 1
8 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM RBC Capital OUTPERFORM Guggenheim BUY Morgan Stanley OVERWEIGHT Wedbush OUTPERFORM HC Wainwright & Co. BUY B of A Securities NEUTRAL Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
SYRE$88.98COMPARE
VERA$35.89COMPARE
IMNM$26.76COMPARE
BCRX$9.96COMPARE
ZYME$29.19COMPARE
NTLA$12.74COMPARE
MAZE$26.21COMPARE
ORIC$12.86COMPARE